The DOI matches its Crossref record; 39 of the 41 references it cites were found in a registry or an index; none of the 13 sources its claims cite is checked for support yet.
One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China: A Longitudinal Cohort Study
Open accessAbstract
Importance: Determining the long-term impact of COVID-19 on cognition is important to inform immediate steps in COVID-19 research and health policy. Objective: To investigate the 1-year trajectory of cognitive changes in older COVID-19 survivors. Design, Setting, and Participants: This cohort study recruited 3233 COVID-19 survivors 60 years and older who were discharged from 3 COVID-19-designated hospitals in Wuhan, China, from February 10 to April 10, 2020. Their uninfected spouses (N = 466) were recruited as a control population. Participants with preinfection cognitive impairment, a concomitant neurological disorder, or a family history of dementia were excluded, as well as those with severe cardiac, hepatic, or kidney disease or any kind of tumor. Follow-up monitoring cognitive functioning and decline took place at 6 and 12 months. A total of 1438 COVID-19 survivors and 438 control individuals were included in the final follow-up. COVID-19 was categorized as severe or nonsevere following the American Thoracic Society guidelines. Main Outcomes and Measures: The main outcome was change in cognition 1 year after patient discharge. Cognitive changes during the first and second 6-month follow-up periods were assessed using the Informant Questionnaire on Cognitive Decline in the Elderly and the Telephone Interview of Cognitive Status-40, respectively. Based on the cognitive changes observed during the 2 periods, cognitive trajectories were classified into 4 categories: stable cognition, early-onset cognitive decline, late-onset cognitive decline, and progressive cognitive decline. Multinomial and conditional logistical regression models were used to identify factors associated with risk of cognitive decline. Results: Among the 3233 COVID-19 survivors and 1317 uninfected spouses screened, 1438 participants who were treated for COVID-19 (691 male [48.05%] and 747 female [51.95%]; median [IQR] age, 69 [66-74] years) and 438 uninfected control individuals (222 male [50.68%] and 216 female [49.32%]; median [IQR] age, 67 [66-74] years) completed the 12-month follow-up. The incidence of cognitive impairment in survivors 12 months after discharge was 12.45%. Individuals with severe cases had lower Telephone Interview of Cognitive Status-40 scores than those with nonsevere cases and control individuals at 12 months (median [IQR]: severe, 22.50 [16.00-28.00]; nonsevere, 30.00 [26.00-33.00]; control, 31.00 [26.00-33.00]). Severe COVID-19 was associated with a higher risk of early-onset cognitive decline (odds ratio [OR], 4.87; 95% CI, 3.30-7.20), late-onset cognitive decline (OR, 7.58; 95% CI, 3.58-16.03), and progressive cognitive decline (OR, 19.00; 95% CI, 9.14-39.51), while nonsevere COVID-19 was associated with a higher risk of early-onset cognitive decline (OR, 1.71; 95% CI, 1.30-2.27) when adjusting for age, sex, education level, body mass index, and comorbidities. Conclusions and Relevance: In this cohort study, COVID-19 survival was associated with an increase in risk of longitudinal cognitive decline, highlighting the importance of immediate measures to deal with this challenge.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
45 Own result · 8 Own method · 7 Not checked yet · 7 Own interpretation · 1 No basis given
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Severe COVID-19 was associated with a higher risk of early-onset cognitive decline (odds ratio [OR], 4.87; 95% CI, 3.30-7.20),late-onset cognitive decline (OR, 7.58; 95% CI, 3.58-16.03),and progressive cognitive decline (OR, 19.00; 95% CI, 9.14-39.51)”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Abstract
plaincorrelationaln = 1,438 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Adjustment for age, sex, education, BMI, and comorbidities is sufficient to control for confounding of the association between COVID-19 and cognitive decline.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Individuals with severe cases had lower Telephone Interview of Cognitive Status-40 scores than those with nonsevere cases and control individuals at 12 months (median [IQR]: severe, 22.50 [16.00-28.00];nonsevere, 30.00 [26.00-33.00];control, 31.00 [26.00-33.00]).”
- Also stated in: § Cognitive Impairment 12 Months After Discharge · plain
“Individuals with severe cases also had lower TICS-40 scores than those with nonsevere cases (median [IQR] severe, 22.50 [16.00-28.00]vs nonsevere, 30.00 [26.00-33.00];P < .001)and control individuals (median [IQR] severe, 22.50 [16.00-28.00]vs control, 31.00 [26.00-33.00];P < .001) at 12 months.”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Exclusion of participants with self-reported or diagnosed preinfection cognitive impairment accurately identifies those without preinfection impairment.
- Also stated in: § Cognitive Impairment 12 Months After Discharge · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The IQCODE score (higher score indicates larger longitudinal cognitive decline) at 6 months' follow-up was higher in individuals with severe cases than in those with nonsevere cases (median [IQR], 3.63 [3.15-4.36]vs 3.18 [3.00-3.56];P < .001)”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Longitudinal Cognitive Change During Follow-up
plaincorrelationaln = 158 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportion of participants with longitudinal cognitive decline during the first 6 months was higher among those with severe cases than those with nonsevere cases (60.77% vs 28.86%; P < .001)”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Longitudinal Cognitive Change During Follow-up
plaincorrelationaln = 158 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and control individuals (median [IQR], 24.00 [18.25-29.00]vs 30.00 [26.00-33.25];P < .001) at 6 months.”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Cognitive Impairment 12 Months After Discharge
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Uninfected spouses are a valid control group for COVID-19 survivors, comparable on factors affecting cognition.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and control individuals (median [IQR], 3.63 [3.15-4.36]vs 3.06 [3.00-3.38];P < .001)”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Longitudinal Cognitive Change During Follow-up
plaincorrelationaln = 158 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Uninfected spouses are a valid control group for COVID-19 survivors, comparable on factors affecting cognition.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Individuals with severe cases had lower TICS-40 scores (indicating worse cognition) than those with nonsevere cases (median [IQR], 24.00 [18.25-29.00]vs 30.00 [26.00-33.00];P < .001)”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Cognitive Impairment 12 Months After Discharge
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Severe COVID-19 was associated with a higher risk of early-onset cognitive decline (odds ratio [OR], 4.87; 95% CI, 3.30-7.20),late-onset cognitive decline (OR, 7.58; 95% CI, 3.58-16.03),and progressive cognitive decline (OR, 19.00; 95% CI, 9.14-39.51)”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Abstract
plaincorrelationaln = 1,438 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Adjustment for age, sex, education, BMI, and comorbidities is sufficient to control for confounding of the association between COVID-19 and cognitive decline.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Severe COVID-19 was associated with a higher risk of early-onset cognitive decline (odds ratio [OR], 4.87; 95% CI, 3.30-7.20),late-onset cognitive decline (OR, 7.58; 95% CI, 3.58-16.03),and progressive cognitive decline (OR, 19.00; 95% CI, 9.14-39.51)”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Abstract
plaincorrelationaln = 1,438 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Adjustment for age, sex, education, BMI, and comorbidities is sufficient to control for confounding of the association between COVID-19 and cognitive decline.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The incidence of cognitive impairment in survivors 12 months after discharge was 12.45%.”
- Also stated in: § Cognitive Impairment 12 Months After Discharge · plain
“The overall incidence of cognitive impairment in survivors 12 months after discharge was 12.45%.”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Abstract
plainn = 1,438- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Exclusion of participants with self-reported or diagnosed preinfection cognitive impairment accurately identifies those without preinfection impairment.
- Also stated in: § Cognitive Impairment 12 Months After Discharge · plain
- It may state two separate claims as one. 5
- Probably not a substantial claim. 3
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In this study, nonsevere COVID-19 was associated with cognitive impairment at 12 months and late-onset cognitive decline in the paired cohort, but not in the whole cohort.”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Discussion
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the participants who completed the 12-month follow-up, COVID-19 survivors were not different from control individuals in age, sex distribution, education level, BMI, and frequency of comorbidities, including hypertension, diabetes, hyperlipidemia, stroke, coronary heart disease, and COPD (Table 1).”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Demographic Characteristics of Participants
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The association between IQCODE and TICS-40 scores was analyzed to ensure the consistency of the 2 cognitive assessments verified in previous studies.20,21”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Cognitive Assessment
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Telephone interviews were conducted to assess cognition by a group of trained raters (L.-R.W., L.J., Y.Y., X.C., Y.L., Y.C).”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Cognitive Assessment
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In the paired subgroup of 438 COVID-19 survivors and their uninfected spouses, survivors were older (median [IQR] age, 68 [65-78] vs 67 [66-74]; P < .001)and had a higher frequency of hypertension (47.03% vs 34.47%; P < .001)than their spouses (eTable 3 in the Supplement).”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Demographic Characteristics of Participants
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“several cross-sectional studies showing that SARS-CoV-2 infection is associated with an increase in risk of cognitive impairment”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Discussion
What the sources say
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Chronic systemic inflammation after SARS-CoV-2 infection exacerbates neurodegeneration, thus potentially leading to long-term cognitive deficits.”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Discussion
What the sources say
- Not checked yetcites [35] source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“the mismatch of sample sizes between survivors and control individuals and the relatively high rate of loss-to-follow-up weakened the power of the findings”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Limitations
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
Adjustment for age, sex, education, BMI, and comorbidities is sufficient to control for confounding of the association between COVID-19 and cognitive decline.
“when adjusting for age, sex, education level, body mass index, and comorbidities.”
The paper relies on this without support.
Exclusion of participants with self-reported or diagnosed preinfection cognitive impairment accurately identifies those without preinfection impairment.
“Participants were excluded if they met the following conditions: (1) did not agree to participate, did not understand the items in the questionnaires, or had communicative obstacles owing to language or hearing reasons; (2) had self-reported or diagnosed cognitive impairment preinfection;”
The paper relies on this without support.
The 1-year follow-up period is sufficient to capture the long-term trajectory of cognitive changes after COVID-19.
“In this study, we investigated the 1-year dynamic trajectory of cognitive changes in older COVID-19 survivors.”
The paper relies on this without support.
Uninfected spouses are a valid control group for COVID-19 survivors, comparable on factors affecting cognition.
“Uninfected spouses who lived with the patients were recruited as control individuals.”
The paper relies on this without support.
The long-term pattern of cognitive change among COVID-19 survivors is still not clear.
“Postinfection cognitive outcomes following COVID-19 have been reported but the long-term dynamic trajectory of cognitive changes in COVID-19 survivors remains unclear.”
The paper relies on this without support.
Cognitive decline may be affected by both preexisting cognitive impairment and COVID-19.
“As cognitive decline might be affected by both preexisting cognitive impairment and COVID-19, we excluded participants with known preexisting cognitive impairment and a family history of dementia.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies have demonstrated an association between COVID-19 and long-term brain atrophy and cognitive impairment in older individuals.282,283”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [282]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Demographic Characteristics of Participants
“hypertension (51.15% vs 47.28%; P < .001)”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Conclusions
“| Hypertension | 561 (39.01) | 133 (51.15) | 426 (36.16) | 151 (34.47) | .09 b | <.001 b |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“control individuals (80 [30.77%] vs 23 [5.25%];P < .001)”
§ One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China A Longitudinal Cohort Study > Longitudinal Cognitive Change During Follow-up
Reported 23 · recomputed 22
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Self-citationJames, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China
Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., Chang, J., Hong, C., Zhou, Y., Wang, D., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1127 · Cited by 7,166
Self-citationA Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
COVID-19 pandemic and mental health consequences: Systematic review of the current evidence
Vindegaard, N., & Benros, M. E. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.05.048 · Cited by 3,221
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0218pp · Cited by 3,187
Taquet, M., Geddes, J. R., Husain, M., Luciano, S., & Harrison, P. J. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00084-5 · Cited by 2,189 · cited 3×
“001) and 12 months (median [IQR], 29 [24-32] vs 31 [26-33]; P < .”
BackgroundTaquet, M., Luciano, S., Geddes, J. R., & Harrison, P. J. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30462-4 · Cited by 1,484
2. Classification and Diagnosis of Diabetes
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s005 · Cited by 1,116
1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study.
Huang, L., Yao, Q., Gu, X., Wang, Q., Ren, L., Wang, Y., Hu, P., Guo, L., Liu, M., Xu, J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01755-4 · Cited by 1,101
Self-citation
Cited by
Sorted by citations
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Self-citationMartin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
Self-citationMartin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z., Anderson, C. A. M., Arora, P. K., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,284
Huang, L., Li, X., Gu, X., Zhang, H., Ren, X., Guo, L., Liu, M., Wang, Y., Cui, D., Wang, Y., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00126-6 · Cited by 613
Self-citationPalaniappan, L. P., Allen, N. B., Almarzooq, Z., Anderson, C. A. M., Arora, P. K., Avery, C. L., Baker-Smith, C. M., Bansal, N., Currie, M. E., Earlie, R. S., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001412 · Cited by 343
Self-citationPathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC)
Sherif, Z. A., Gómez, C. R., Connors, T. J., Henrich, T. J., Reeves, W. B., & RECOVER Mechanistic Pathway Task Force (2023) · eLife · doi:10.7554/elife.86002 · Cited by 248
Multimodal neuroimaging in post-COVID syndrome and correlation with cognition
Díez‐Cirarda, M., Yus, M., Gómez‐Ruiz, N., Polidura, C., Gil‐Martínez, L., Delgado‐Alonso, C., Jorquera, M., Gómez‐Pinedo, U., Matías‐Guiu, J., Arrazola, J., et al. (2022) · Brain · doi:10.1093/brain/awac384 · Cited by 221
Fatigue and cognitive impairment after COVID-19: A prospective multicentre study
Hartung, T. J., Neumann, C., Bahmer, T. J., Chaplinskaya-Sobol, I., Endres, M., Geritz, J., Hæusler, K. G., Heuschmann, P. U., Hildesheim, H., Hinz, A., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101651 · Cited by 168
Lobanov‐Rostovsky, S., He, Q., Chen, Y., Liu, Y., Wu, Y., Liu, Y., Venkatraman, T. M., French, E., Curry, N., Hemmings, N., et al. (2023) · BMC Public Health · doi:10.1186/s12889-023-15583-1 · Cited by 163
Self-citationAntiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
Self-citationMansell, V. E., Dykgraaf, S. H., Kidd, M. R., & Goodyear‐Smith, F. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00245-8 · Cited by 160
COVID-19 and cognitive impairment: neuroinvasive and blood‒brain barrier dysfunction
Chen, Y., Yang, W., Chen, F., & Cui, L. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02579-8 · Cited by 134
Self-citationLong Covid: where we stand and challenges ahead
Mantovani, A., Morrone, M. C., Patrono, C., Santoro, M., Schiaffino, S., Remuzzi, G., Bussolati, G., On behalf of the Covid-19 Commission of the Accademia Nazionale dei Lincei, Cappuccinelli, P., Fitzgerald, G., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01052-6 · Cited by 124
Quan, M., Wang, X., Gong, M., Wang, Q., Li, Y., & Jia, J. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100836 · Cited by 105
Self-citationEffects of COVID-19 on cognition and brain health
Zhao, S., Toniolo, S., Hampshire, A., & Husain, M. (2023) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2023.08.008 · Cited by 90
Risk of long COVID main symptoms after SARS-CoV-2 infection: a systematic review and meta-analysis
Marjenberg, Z. R., Leng, S. X., Tascini, C., Garg, M., Misso, K., Guerche‐Séblain, C. E., & Shaikh, N. (2023) · Scientific Reports · doi:10.1038/s41598-023-42321-9 · Cited by 77
Insulin Resistance in Peripheral Tissues and the Brain: A Tale of Two Sites
Rhea, E. M., Banks, W. A., & Raber, J. (2022) · Biomedicines · doi:10.3390/biomedicines10071582 · Cited by 76
Preliminary Guidelines for the Clinical Evaluation and Management of Long COVID
Kim, Y., Kim, S. E., Kim, T., Yun, K. W., Lee, S. H., Lee, E. J., Seo, J.-W., Jung, Y. H., & Chong, Y. P. (2022) · Infection and Chemotherapy · doi:10.3947/ic.2022.0141 · Cited by 65
Brain fog as a Long-term Sequela of COVID-19
Nouraeinejad, A. (2022) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-022-01352-5 · Cited by 72
Rahmati, M., Yon, D. K., Lee, S. W., Soysal, P., Koyanagi, A., Jacob, L., Li, Y., Park, J. M., Kim, Y. W., Shin, J. I., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28909 · Cited by 64
Self-citationCognitive impairment after long COVID-19: current evidence and perspectives
Li, Z., Zhang, Z., Zhang, Z., Wang, Z., & Li, H. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1239182 · Cited by 70
Chilunga, F. P., Appelman, B., van Vugt, M., Kalverda, K. A., Smeele, P. J., van Es, J., Wiersinga, W. J., Rostila, M., Prins, M., Stronks, K., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100630 · Cited by 56
Cognitive Symptoms of Post–COVID-19 Condition and Daily Functioning
Jaywant, A., Gunning, F. M., Oberlin, L. E., Santillana, M., Ognyanova, K., Druckman, J. N., Baum, M., Lazer, D. M. J., & Perlis, R. H. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.56098 · Cited by 60
Dynamic white matter changes in recovered COVID-19 patients: a two-year follow-up study
Huang, S., Zhou, X., Zhao, W., Du, Y., Yang, D., Huang, Y., Chen, Y., Zhang, H., Yang, G., Liu, J., et al. (2023) · Theranostics · doi:10.7150/thno.79902 · Cited by 55
Self-citationNatural history of long-COVID in a nationwide, population cohort study
Hastie, C. E., Lowe, D. J., McAuley, A., Mills, N. L., Winter, A., Black, C., Scott, J. T., O’Donnell, C. A., Blane, D., Browne, S. E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39193-y · Cited by 51
Dubey, S., Das, S., Ghosh, R., Dubey, M. J., Chakraborty, A. P., Roy, D., Das, G. C., Dutta, A., Santra, A., Sengupta, S., et al. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220090 · Cited by 51
The kynurenine pathway relates to post‐acute COVID ‐19 objective cognitive impairment and PASC
Cysique, L. A., Jakabek, D., Bracken, S. G., Allen‐Davidian, Y., Heng, B., Chow, S., Dehhaghi, M., Pires, A. S., Darley, D. R., Byrne, A., et al. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51825 · Cited by 77
Houben, S., & Bonnechère, B. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19137748 · Cited by 52
Long COVID: Clinical Framing, Biomarkers, and Therapeutic Approaches
Conti, V., Corbi, G., Sabbatino, F., Pascale, D. D., Sellitto, C., Stefanelli, B., Bertini, N., Simone, M. D., Liguori, L., Paola, I. D., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020334 · Cited by 46
Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness
Pandharipande, P. P., Roberson, S. W., Harrison, F. E., Wilson, J. E., Bastarache, J. A., & Ely, E. W. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00238-2 · Cited by 46
Healthy outcomes of patients with COVID-19 two years after the infection: a prospective cohort study
Li, D., Liao, X., Liu, Z., Ma, Z., Dong, J., Zheng, G., Zi, M., Wang, F., He, Q., Li, G., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2133639 · Cited by 44
Myelin dysfunction in aging and brain disorders: mechanisms and therapeutic opportunities
Huang, Z., Zhang, Y., Zou, P., Zong, X., & Zhang, Q. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00861-w · Cited by 49
COVID-19 as a Risk Factor for Alzheimer’s Disease
Golzari-Sorkheh, M., Weaver, D. F., & Reed, M. A. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-220800 · Cited by 39
The type I interferon antiviral response in the choroid plexus and the cognitive risk in COVID-19
Suzzi, S., Tsitsou-Kampeli, A., & Schwartz, M. (2023) · Nature Immunology · doi:10.1038/s41590-022-01410-z · Cited by 37
Kim, Y., Bae, S., Chang, H., & Kim, S.-W. (2024) · Scientific Reports · doi:10.1038/s41598-023-50024-4 · Cited by 37
Mudgal, S. K., Gaur, R., Rulaniya, S., Latha, T., Agarwal, R. K., Kumar, S., Varshney, S., Sharma, S. K., Bhattacharya, S., & Kalyani, V. C. (2023) · Cureus · doi:10.7759/cureus.36325 · Cited by 34
Chang, L., Ryan, M. C., Liang, H., Zhang, X., Cunningham, E. P., Wang, J. L., Wilson, E. M. P., Herskovits, E. H., Kottilil, S., & Ernst, T. (2023) · Neurology · doi:10.1212/wnl.0000000000207309 · Cited by 34
The Olfactory System: Basic Anatomy and Physiology for General Otorhinolaryngologists
Han, S. A., Kim, J. K., Cho, D., Patel, Z. M., & Rhee, C. (2023) · Clinical and Experimental Otorhinolaryngology · doi:10.21053/ceo.2023.00185 · Cited by 40
Fewer COVID‐19 Neurological Complications with Dexamethasone and Remdesivir
Grundmann, A., Wu, C., Hardwick, M., Baillie, J. K., Openshaw, P., Semple, M. G., Böhning, D., Pett, S. L., Michael, B. D., Thomas, R. H., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26536 · Cited by 32
Merla, L., Montesi, M. C., Ticali, J., Bais, B., Cavarape, A., & Colussi, G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051845 · Cited by 30
Liu, T. C., Yoo, S. M., Sim, M., Motwani, Y., Viswanathan, N., & Wenger, N. S. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.11974 · Cited by 30
The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines
Sun, Z., Wu, T., Xie, H., Li, Y., Zhang, J., Su, X., & Qi, H. (2022) · Vaccines · doi:10.3390/vaccines10071103 · Cited by 29
Self-citationPost-acute sequelae of COVID-19 in older persons: multi-organ complications and mortality
Wan, E. Y. F., Zhang, R., Mathur, S., Yan, V. K. C., Lai, F. T. T., Chui, C. S. L., Li, X., Wong, C. K. H., Chan, E. W., Lau, C. S., et al. (2023) · Journal of Travel Medicine · doi:10.1093/jtm/taad082 · Cited by 30
Cysique, L. A., Jakabek, D., Bracken, S. G., Allen‐Davidian, Y., Heng, B., Chow, S., Dehhaghi, M., Pires, A. S., Darley, D. R., Byrne, A., et al. (2022) · medRxiv · doi:10.1101/2022.06.07.22276020 · Cited by 28
Escobar, A. P., Bonansco, C., Cruz, G., Dagnino‐Subiabre, A., Fuenzalida, M., Negrón-Oyarzo, I., Sotomayor‐Zárate, R., Martínez-Pinto, J., & Jorquera, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210083 · Cited by 35
Shan, D., Wang, C., Crawford, T. J., & Holland, C. (2024) · BMC Geriatrics · doi:10.1186/s12877-024-05538-5 · Cited by 27
Wesselingh, R. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.52063 · Cited by 25
Neurological complications of COVID-19
Dai, X., Cao, X., Jiang, Q., Wu, B., Lou, T., Shao, Y., Hu, Y., & Lan, Q. (2022) · QJM · doi:10.1093/qjmed/hcac272 · Cited by 26
Szewczyk, W., Fitzpatrick, A. L., Fossou, H., Gentile, N. L., Sotoodehnia, N., Vora, S. B., West, T. E., Bertolli, J., Cope, J. R., Lin, J.-M. S., et al. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-10158-w · Cited by 31
Li, S., Han, L., Shi, H., Chong, K. C., Zhao, S., & Ran, J. (2022) · Age and Ageing · doi:10.1093/ageing/afac277 · Cited by 23
Chaganti, J. R., Poudel, G. R., Cysique, L. A., Dore, G. J., Kelleher, A. D., Matthews, G., Darley, D. R., Byrne, A., Jakabek, D., Zhang, X., et al. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1350848 · Cited by 24
Changes in memory and cognition during the SARS-CoV-2 human challenge study
Trender, W. R., Hellyer, P. J., Killingley, B., Kalinova, M., Mann, A., Catchpole, A. P., Menon, D. K., Needham, E., Thwaites, R. S., Chiu, C., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102842 · Cited by 22
Axenhus, M., Frederiksen, K. S., Zhou, R. Z., Waldemar, G., & Winblad, B. G. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-03602-6 · Cited by 22
SARS-CoV-2 infection and immune responses
Harne, R., Williams, B., Abdelaal, H. F. M., Baldwin, S. L., & Coler, R. N. (2023) · AIMS Microbiology · doi:10.3934/microbiol.2023015 · Cited by 21
Cognitive impairment in post-acute COVID-19 syndrome: a scoping review
Cipolli, G. C., Alonso, V., Yasuda, C. L., de Assumpção, D., Cachioni, M., de Melo, R. C., Hinsliff‐Smith, K., & Yassuda, M. S. (2023) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0043-1777115 · Cited by 22
Neuropsychological Measures of Long COVID-19 Fog in Older Subjects
Lauria, A., Carfì, A., Benvenuto, F., Bramato, G., Ciciarello, F., Rocchi, S., Rota, E., Salerno, A., Stella, L., Tritto, M., et al. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2022.05.003 · Cited by 25
Update on modifiable risk factors for Alzheimer's disease and related dementias
Jaisa-aad, M., Muñoz‐Castro, C., & Serrano‐Pozo, A. (2024) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001243 · Cited by 21
Subjective brain fog: a four-dimensional characterization in 25,796 participants
Alim‐Marvasti, A., Ciocca, M., Kuleindiren, N., Lin, A., Selim, H., & Mahmud, M. (2024) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2024.1409250 · Cited by 25
Tracking cognitive trajectories in older survivors of COVID-19 up to 2.5 years post-infection
Liu, Y.-H., Wu, Q.-X., Wang, Q.-H., Zhang, Q.-F., Tang, Y., Liu, D., Wang, J.-J., Liu, X.-Y., Wang, L.-R., Li, L., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00667-3 · Cited by 20
Self-citationAssociations of hospital-treated infections with subsequent dementia: nationwide 30-year analysis
Richmond‐Rakerd, L. S., Iyer, M. T., D’Souza, S., Khalifeh, L., Caspi, A., Moffitt, T. E., & Milne, B. J. (2024) · Nature Aging · doi:10.1038/s43587-024-00621-3 · Cited by 20
Acute and long-term effects of COVID-19 on brain and mental health: A narrative review
Bremner, J. D., Russo, S. J., Gallagher, R., & Simon, N. M. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.11.007 · Cited by 19
Risk of new-onset dementia following COVID-19 infection: a systematic review and meta-analysis
Zhang, Q., Botta, R., Xu, Y., Wei, J. C., & Tung, T. (2025) · Age and Ageing · doi:10.1093/ageing/afaf046 · Cited by 20
Development of an artificial intelligence‐based diagnostic model for Alzheimer's disease
Fujita, K., Katsuki, M., Takasu, A., Kitajima, A., Shimazu, T., & Maruki, Y. (2022) · Aging Medicine · doi:10.1002/agm2.12224 · Cited by 21
Long COVID neuropsychological follow-up: Is cognitive rehabilitation relevant?
Braga, L. W., de Oliveira, S. B., Moreira, A. S., Pereira, M. E. M. D. S. M., Serio, A., Carneiro, V. D. S., Freitas, L. D. F. P., & Souza, L. M. D. N. (2023) · Neurorehabilitation · doi:10.3233/nre-230212 · Cited by 20
Dissipating the fog: Cognitive trajectories and risk factors 1 year after COVID‐19 hospitalization
Gonçalves, N. G., Aliberti, M. J. R., Bertola, L., Avelino‐Silva, T. J., Dias, M. B., Apolinário, D., Busatto, G. F., Forlenza, O. V., Nitríni, R., Brucki, S. M. D., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12993 · Cited by 17
Vakani, K., Ratto, M., Sandford-James, A., Antonova, E., & Kumari, V. (2023) · European Psychiatry · doi:10.1192/j.eurpsy.2023.25 · Cited by 18
Alterations in microbiota of patients with COVID‐19: implications for therapeutic interventions
Qiu, Y., Mo, C., Chen, L., Ye, W., Chen, G., & Zhu, T. (2024) · MedComm · doi:10.1002/mco2.513 · Cited by 18
Zhao, P., Zhang, G., Wang, Y., Chun-xiao, W., Wang, Z., Zhai, W., Shen, Y., Shi, L., & Sun, L. (2024) · Scientific Reports · doi:10.1038/s41598-024-67172-w · Cited by 17
Self-citationShrestha, A., Chen, R., Kunasekaran, M. P., Honeyman, D., Notaras, A., Sutton, B. P., Quigley, A. L., & MacIntyre, C. R. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102448 · Cited by 20
Long-term outcomes of patients with a pre-existing neurological condition after SARS-CoV-2 infection
Hadidchi, R., Al‐Ani, Y., Choi, S., Renteria, S., Duong, K. S., Henry, S. S., Wang, S. H., & Duong, T. Q. (2025) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2025.123477 · Cited by 17
Hall, P. A., Ayaz, H., Meng, G., Hudson, A., Sakib, M. N., Quah, A. C. K., Agar, T. K., Lee, J. A., Boudreau, C., & Fong, G. T. (2023) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2023.100595 · Cited by 16
Neurological and Psychiatric Manifestations of Post-COVID-19 Conditions
Jung, Y. H., Ha, E.-H., Park, J., Choe, K. W., Lee, W. J., & Jo, D. H. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e83 · Cited by 16
Knopman, D. S., Laskowitz, D. T., Attix, D. K., Charvet, L. E., Becker, J., Federman, A. D., Wisnivesky, J. P., Mahncke, H. W., Vleet, T. V., Bateman, L., et al. (2024) · Trials · doi:10.1186/s13063-024-08156-z · Cited by 16
Meta-analysis of Cognitive Function Following Non-severe SARS-CoV-2 Infection
Austin, T. A., Thomas, M. L., Lü, M., Hodges, C. B., Darowski, E. S., Bergmans, R. S., Parr, S., Pickell, D., Catazaro, M., Lantrip, C., et al. (2024) · Neuropsychology Review · doi:10.1007/s11065-024-09642-6 · Cited by 17
Reppas‐Rindlisbacher, C. E., Boblitz, A., Fowler, R., Lapointe‐Shaw, L., Sheehan, K., Stukel, T. A., & Rochon, P. A. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.27750 · Cited by 15
Neuropsychology practice guidance for the neuropsychiatric aspects of Long COVID
Koterba, C., Considine, C. M., Becker, J., Hoskinson, K. R., Ng, R., Vargas, G., Basso, M. R., Puente, A. E., Lippa, S. M., & Whiteside, D. M. (2024) · The Clinical Neuropsychologist · doi:10.1080/13854046.2024.2392943 · Cited by 15
Goetzl, E. J., Yao, P. J., & Kapogiannis, D. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.03.026 · Cited by 15
Acute and long-term neurological disorders in patients with coronavirus infection
Parfenov, V. A., & Kulesh, A. A. (2022) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2022-3-4-11 · Cited by 14
Cognitive and mental health outcomes in long covid
Aretouli, E., Malik, M., Widmann, C., Parker, A. M., Oh, E. S., & Vannorsdall, T. D. (2025) · BMJ · doi:10.1136/bmj-2024-081349 · Cited by 21
Gollop, C., Zingel, R., Jacob, L., Smith, L., Koyanagi, A., & Kostev, K. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221271 · Cited by 13
The Multifaceted Manifestations of Multisystem Inflammatory Syndrome during the SARS-CoV-2 Pandemic
Gómez, H. R. P., Morfín‐Otero, R., González-Díaz, E., Esparza-Ahumada, S., León-Garnica, G., & Rodríguez-Noriega, E. (2022) · Pathogens · doi:10.3390/pathogens11050556 · Cited by 12
COVID-19 in the perioperative setting: A review of the literature and the clinical landscape
O’Glasser, A. Y., & Schenning, K. J. (2022) · Perioperative Care and Operating Room Management · doi:10.1016/j.pcorm.2022.100272 · Cited by 12
Cognitive inhibition deficit in long COVID-19: An exploratory study
Saucier, J., José, C., Beroual, Z., Al-Qadi, M., Chartrand, S., Libert, E., Losier, M.-C., Cooling, K., Girouard, G., Jbilou, J., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1125574 · Cited by 14
Boesl, F., Goereci, Y., Schweitzer, F., Finke, C., Schild, A., Bittner, S., Steffen, F., Schröder, M., Quitschau, A., Heine, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-55881-1 · Cited by 14
SARS-CoV-2 membrane protein induces neurodegeneration via affecting Golgi-mitochondria interaction
Wang, F., Han, H., Wang, C., Wang, J., Peng, Y., Chen, Y., He, Y., Deng, Z., Li, F., Rong, Y. S., et al. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00458-1 · Cited by 13
Self-citationBrain Health After COVID-19, Pneumonia, Myocardial Infarction, or Critical Illness
Peinkhofer, C., Zarifkar, P., Christensen, R. H. B., Nersesjan, V., Fonsmark, L., Mérie, C., Lebech, A., Katzenstein, T. L., Bang, L. E., Kjærgaard, J., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.49659 · Cited by 14
COVID-19 infection associated with increased risk of new-onset vascular dementia in adults ≥50 years
Shan, D., Xu, Y., Yang, C., Crawford, T. J., & Holland, C. (2025) · npj Dementia · doi:10.1038/s44400-025-00034-y · Cited by 12
Wesselingh, R., & Wesselingh, S. L. (2023) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.14221 · Cited by 10
Voruz, P., de Alcântara, I. J., Nuber‐Champier, A., Cionca, A., Guérin, D., Allali, G., Benzakour, L., Lalive, P. H., Lövblad, K., Braillard, O., et al. (2024) · Journal of Global Health · doi:10.7189/jogh.14.05008 · Cited by 10
Barilaite, E., Watson, H., & Hocaoğlu, M. (2024) · Journal of patient-centered research and reviews · doi:10.17294/2330-0698.2041 · Cited by 10
Cahan, J. G., Finley, J. A., Cotton, E., Orban, Z. S., Jimenez, M., Weıntraub, S., Sorets, T. R., & Koralnik, I. J. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1401796 · Cited by 10
Melillo, A., Perrottelli, A., Caporusso, E., Coltorti, A., Giordano, G. M., Giuliani, L., Pezzella, P., Bucci, P., Mucci, A., Galderisi, S., et al. (2024) · European Psychiatry · doi:10.1192/j.eurpsy.2024.1770 · Cited by 15
Long-Term Trajectories of Cognitive Disability Among Older Adults Following a Major Disaster
Hu, H., Li, B., Hikichi, H., Kawachi, I. I., & Li, X. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.48277 · Cited by 10
Yuda, G. P. W. C., Hanif, N., & Hermawan, A. (2023) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-023-00484-w · Cited by 10
Neurological complications of critically ill COVID-19 patients
Sonneville, R., Dangayach, N. S., & Newcombe, V. (2023) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001029 · Cited by 10
Araújo, N., Silva, I., Campos, P., Correia, R., Calejo, M., Freitas, P., Seco, M., Ribeiro, L., Costa, A. R., Morais, S., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-072981 · Cited by 11
Cholesterol 24-hydroxylase at the choroid plexus contributes to brain immune homeostasis
Tsitsou-Kampeli, A., Suzzi, S., Kenigsbuch, M., Satomi, A., Strobelt, R., Singer, O., Feldmesser, E., Purnapatre, M., Colaiuta, S. P., David, E., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101278 · Cited by 9
Symptom Burden among Older COVID-19 Survivors Two Years after Hospital Discharge
Zhang, Y., Han, Z., Dai, Y., Liu, Y., Wang, Q., Cheng, L., Xiong, C., Hou, C., Yang, X., Ye, Y., et al. (2023) · Aging and Disease · doi:10.14336/ad.2023.0304 · Cited by 9
Self-citationOh my gut! Is the microbial origin of neurodegenerative diseases real?
Walker, A. C., & Czyż, D. M. (2023) · Infection and Immunity · doi:10.1128/iai.00437-22 · Cited by 11
Wang, W., Cui, R., Leng, L., Wang, G., & Peng, G. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230172 · Cited by 9
Metadata
- Authors
- Liu, Y.-H., Chen, Y., Wang, Q.-H., Wang, L.-R., Jiang, L., Yang, Y., Chen, X., Li, Y., Cen, Y., Xu, C., Zhu, J., Li, W., Wang, Y.-R., Zhang, L.-L., Liu, J., Xu, Z.-Q., & Wang, Y.-J.
- Affiliations
- Army Medical University (CN)
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
- Department of Oncology, General Hospital of the Central Theatre Command of the People’s Liberation Army, Wuhan, China
- Corresponding author
- Wang, Yan-Jiang
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2022-05-01
- Volume
- 79
- Issue
- 5
- Pages
- 509
- ISSN
- 2168-6149 (ISSN-L)
- PMC
- PMC8905512
- OpenAlex
- W4220684118
- Cited by
- 225
- References
- 41
- Citations by year
- 2026: 16 · 2025: 32 · 2024: 54 · 2023: 83 · 2022: 39
- FWCI
- 27.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Neurology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81930028)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Intensive Care Unit Cognitive Disorders
- Social Sciences › Psychology › Clinical Psychology › COVID-19 and Mental Health
- Keywords
- COVID-19 pandemic, cognitive decline, older adults, long-term cognitive outcomes, cognitive trajectories, post-COVID cognitive impairment, risk factors for cognitive decline, severe COVID-19, long COVID, Wuhan, SARS-CoV-2, dementia risk, hypertension
- MeSH terms
- COVID-19, SARS-CoV-2, Aged, Cognition, Female, Humans, Longitudinal Studies, Male, Cohort Studies, Survivors, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
